| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1471-4159.1988.TB02497.X |
| P698 | PubMed publication ID | 3373218 |
| P50 | author | Rémi Quirion | Q3456064 |
| Paul A. Lapchak | Q37838905 | ||
| P2093 | author name string | Gauthier S | |
| Robitaille Y | |||
| Araujo DM | |||
| P2860 | cites work | Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type | Q48298226 |
| Nicotinic acetylcholine binding sites in Alzheimer's disease | Q48354475 | ||
| Autoradiographic distribution of muscarinic [3H]acetylcholine receptors in rat brain: comparison with antagonists | Q48355293 | ||
| Brain muscarinic receptors in senile dementia | Q48479457 | ||
| Comparative localization of putative pre- and postsynaptic markers of muscarinic cholinergic nerve terminals in rat brain | Q48488475 | ||
| Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer-type. | Q48670250 | ||
| Autoradiographic localization of muscarinic cholinergic receptors in the hippocampus of patients with senile dementia | Q48922425 | ||
| Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain. | Q53310228 | ||
| Neurotransmitter-related enzymes in senile dementia of the alzheimer type | Q39262591 | ||
| The effects of nicotine on brain neurotransmitter systems | Q40088328 | ||
| Pre- and postsynaptic neurochemical alterations in Alzheimer's disease | Q40196582 | ||
| Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: relation to cholinergic nuclei and projections | Q41473865 | ||
| [3H]oxotremorine-M binding to membranes prepared from rat brain and heart: evidence for subtypes of muscarinic receptors | Q41583158 | ||
| Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities | Q41984049 | ||
| Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase | Q42455258 | ||
| Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease | Q42526718 | ||
| Theodor Meynert: foreshadowing modern concepts of neuropsychiatric pathophysiology | Q42527231 | ||
| Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease | Q44466201 | ||
| Autoradiographic localization of nicotinic receptor binding in rat brain using [3H]methylcarbamylcholine, a novel radioligand | Q48170018 | ||
| Human brain receptor autoradiography using whole hemisphere sections: a general method that minimizes tissue artefacts | Q48258809 | ||
| Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains | Q48265799 | ||
| [3H]methylcarbamylcholine, a new radioligand for studying brain nicotinic receptors | Q48268940 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1914-1923 | |
| P577 | publication date | 1988-06-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. | |
| P478 | volume | 50 |
| Q38782451 | 'From past to future' - deciphering the molecular basis of Alzheimer's disease through the pages of the Journal of Neurochemistry |
| Q21651042 | A Novel Prolyl Endopeptidase Inhibitor, JTP-4819 - Its Behavioral and Neurochemical Properties for the Treatment of Alzheimer's Disease |
| Q52044089 | A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. |
| Q48737824 | A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease |
| Q47949529 | Age-related changes in neuronal nicotinic acetylcholine receptor subunit alpha4 expression are modified by long-term nicotine administration. |
| Q34160761 | Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies |
| Q37541381 | Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. |
| Q48249377 | Antisense oligodeoxynucleotides against the muscarinic m2, but not m4, receptor supports its role as autoreceptors in the rat hippocampus |
| Q31911220 | Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. |
| Q48253436 | Autoradiographic comparison of cholinergic and other transmitter receptors in the normal human hippocampus |
| Q48654715 | Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease |
| Q40783858 | Autoradiographic distribution of putative muscarinic receptor sub-types in mammalian brain. |
| Q48895102 | Autoradiographic evidence that (R)-3-quinuclidinyl (S)-4-fluoromethylbenzilate ((R,S)-FMeQNB) displays in vivo selectivity for the muscarinic m2 subtype |
| Q48462248 | Autoradiographic mapping of cerebral blood flow responses to cholinergic stimulation of the rat substantia innominata: modulatory effect of galanin |
| Q30494501 | Aversive stimulus attenuates impairment of acquisition in a delayed match to position T-maze task caused by a selective lesion of septo-hippocampal cholinergic projections |
| Q43727698 | BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease |
| Q71283690 | Behaviour-related effects of nicotine on slow EEG waves in basal nucleus-lesioned rats |
| Q41701369 | Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? |
| Q34997783 | Brain aging and Alzheimer's disease; use it or lose it. |
| Q48591280 | Brain-derived neurotrophic factor is reduced in Alzheimer's disease |
| Q42522923 | Central muscarinic cholinergic M1 and M2 receptor changes in congenital ornithine transcarbamylase deficiency |
| Q67856020 | Changes of muscarinic cholinergic binding by lymphocytes in parkinson's disease with and without dementia |
| Q59449478 | Chapter II Neurobiology and neuropathology of the human hypothalamus |
| Q71798646 | Characterization of in vivo brain muscarinic acetylcholine receptor subtype selectivity by competition studies against (R,S)-[125I]QNB |
| Q38788038 | Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease |
| Q37130148 | Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme |
| Q37217895 | Cholinergic components of frontal lobe function and dysfunction |
| Q36464551 | Cholinergic forebrain degeneration in the APPswe/PS1DeltaE9 transgenic mouse. |
| Q41755714 | Cholinergic immunolesions by 192IgG-saporin--useful tool to simulate pathogenic aspects of Alzheimer's disease |
| Q40809322 | Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release. |
| Q72059843 | Cholinergic markers in aged cognitively impaired long-evans rats |
| Q37163279 | Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. |
| Q52113470 | Cholinomimetic activities of minaprine. |
| Q46573123 | Comparison of noninvasive quantification methods of in vivo vesicular acetylcholine transporter using [123I]-IBVM SPECT imaging |
| Q41902861 | Comparison of the effects of Alzheimer's disease, normal aging and scopolamine on human transient visual evoked potentials |
| Q33830572 | Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease |
| Q48097064 | Counteractive effects of a partial (sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area |
| Q60325187 | Development of a pharmacological target profile for muscarinic agonists |
| Q73302989 | Diminution of nicotinic receptor alpha 3 subunit mRNA expression in aged rat brain |
| Q28565564 | Distribution of prolyl endopeptidase activities in rat and human brain |
| Q52027740 | Dopamine D-5 receptor modulates hippocampal acetylcholine release. |
| Q33496464 | Downregulation of PEBP1 in rat brain cortex in hypoxia |
| Q49142614 | Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain |
| Q42478368 | Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis |
| Q74379399 | Effects of NIK-247 and tacrine on muscarinic receptor subtypes in rats |
| Q42469079 | Effects of cholinergic-rich neural grafts on radial maze performance of rats after excitotoxic lesions of the forebrain cholinergic projection system--II. Cholinergic drugs as probes to investigate lesion-induced deficits and transplant-induced func |
| Q52057314 | Effects of disrupting the cholinergic system on short-term spatial memory in rats. |
| Q34170235 | Enhanced dendritic spine number of neurons of the prefrontal cortex, hippocampus, and nucleus accumbens in old rats after chronic donepezil administration |
| Q43760349 | Enhancement of learning capacity and cholinergic synaptic function by carnitine in aging rats |
| Q48176936 | Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein |
| Q48618760 | Fingolimod affects gene expression profile associated with LPS-induced memory impairment |
| Q68010936 | Flash and pattern reversal visual evoked responses in normal and demented elderly |
| Q39336083 | Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease. |
| Q29397943 | Human neuronal nicotinic receptors |
| Q48119453 | Human striatum: Chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease |
| Q36743706 | Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders |
| Q44440615 | Impaired Modulation of GABAergic Transmission by Muscarinic Receptors in a Mouse Transgenic Model of Alzheimer's Disease |
| Q53340186 | In vitro and in vivo m2 muscarinic subtype selectivity of some dibenzodiazepinones and pyridobenzodiazepinones. |
| Q23917153 | In vitro and in vivo modulation of cholinergic muscarinic receptors in rat lymphocytes and brain by cholinergic agents |
| Q48812124 | In vivo autoradiography of radioiodinated (R)-3-quinuclidinyl (S)-4-iodobenzilate [(R, S)-IQNB] and (R)-3-quinuclidinyl (R)-4-iodobenzilate [(R,R)-IQNB]. Comparison of the radiolabelled products of a novel tributylstannyl precursor with those of the |
| Q48343957 | In vivo competition studies of Z-(-,-)-[125I]IQNP against 3-quinuclidinyl 2-(5-bromothienyl)-2-thienylglycolate (BrQNT) demonstrating in vivo m2 muscarinic subtype selectivity for BrQNT. |
| Q57317974 | Increased CSF HVA response to arecoline challenge in Alzheimer's disease |
| Q48826879 | Increased muscarinic receptor messenger RNA in Alzheimer's disease temporal cortex demonstrated by in situ hybridization histochemistry |
| Q24314236 | Infracortical interstitial cells concurrently expressing m2-muscarinic receptors, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate-diaphorase in the human and monkey cerebral cortex |
| Q48591069 | Insulin-like growth factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus |
| Q42080582 | L-689,660, a novel cholinomimetic with functional selectivity for M1 and M3 muscarinic receptors |
| Q53311334 | Lesion with the neurotoxin AF64A alters hippocampal cholinergic receptor function |
| Q52029489 | Longitudinal study on oral health in subjects with Alzheimer's disease. |
| Q51557957 | Low plasma epinephrine in elderly female subjects of dementia of Alzheimer type. |
| Q33881450 | Mapping of human and macaque sensorimotor areas by integrating architectonic, transmitter receptor, MRI and PET data |
| Q52166697 | Maternal care, hippocampal synaptogenesis and cognitive development in rats. |
| Q40443903 | Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging |
| Q42474603 | Modest cholinergic deafferentation fails to alter hippocampal G-proteins. |
| Q44063250 | Muscarinic M1 receptor agonists: can they improve cognitive performance? |
| Q48241160 | Muscarinic acetylcholine receptor status in Alzheimer's disease assessed using (R, R) 123I-QNB SPECT. |
| Q44269773 | Muscarinic cholinoceptive neurons in the frontal cortex in Alzheimer's disease |
| Q44410457 | Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease |
| Q37954379 | Muscarinic receptors: their roles in disorders of the central nervous system and potential as therapeutic targets. |
| Q38727137 | N-[3H]methylcarbamylcholine binding sites in the rat and human brain: relationship to functional nicotinic autoreceptors and alterations in Alzheimer's disease. |
| Q36501962 | Neurotransmitters and Neuropeptides in Alzheimer's Disease |
| Q34655902 | Nicotine's effect on neural and cognitive functioning in an aging population |
| Q28139928 | Nicotine, brain nicotinic receptors, and neuropsychiatric disorders |
| Q36932233 | Nicotinic Cholinergic Receptors in Human Brain: Effects of Aging and Alzheimer |
| Q53189482 | Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. |
| Q52081673 | Nicotinic systems and cognitive function |
| Q48716453 | Noradrenergic DSP-4 lesions aggravate impairment of working memory produced by hippocampal muscarinic blockade in rats |
| Q73340104 | Pharmacokinetic computer simulations of the relationship between in vivo and in vitro neuroreceptor subtype selectivity of radioligands |
| Q48925282 | Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes |
| Q28343040 | Pharmacological characterization of a novel muscarinic partial agonist, YM796, in transfected cells expressing the m1 or m2 muscarinic receptor gene |
| Q47755412 | Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain--an in vivo microdialysis study |
| Q48545945 | Pharmacological characterization of the vesamicol analogue (+)-[(125)I]MIBT in primate brain |
| Q40912774 | Pharmacology of nerve growth factor in the brain |
| Q58842921 | Potential therapeutic targets for Alzheimer’s disease |
| Q34400492 | Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases |
| Q63437487 | Preclinical progress with CHF2819, a novel orally active acetylcholinesterase inhibitor |
| Q34415708 | Presynaptic nicotinic ACh receptors |
| Q33925880 | RACK1 is involved in β-amyloid impairment of muscarinic regulation of GABAergic transmission |
| Q35540380 | Reactivation of atrophic neurons in Alzheimer's disease |
| Q42460615 | Reduction in acetylcholine release in the hippocampus of dopamine D5 receptor-deficient mice |
| Q48103246 | Regional covariance of muscarinic acetylcholine receptors in Alzheimer's disease using (R, R) [(123)I]-QNB SPECT. |
| Q48389534 | SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome |
| Q43276061 | Scopolamine induced amnesia is reversed by Bacopa monniera through participation of kinase-CREB pathway |
| Q44317349 | Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. |
| Q34166264 | Selective cholinergic depletion in medial septum leads to impaired long term potentiation and glutamatergic synaptic currents in the hippocampus |
| Q42523003 | Selective lesion of cholinergic neurons in the medial septum by 192 IgG-saporin impairs learning in a delayed matching to position T-maze paradigm |
| Q37113432 | Selective lesion of septal cholinergic neurons in rats impairs acquisition of a delayed matching to position T-maze task by delaying the shift from a response to a place strategy |
| Q43517578 | Synthesis and biological characterization of stable and radioiodinated (+/-)-trans-2-hydroxy-3-P[4-(3-iodophenyl)piperidyl]-1,2,3,4-tetrahydronaphthalene (3'-IBVM). |
| Q34441061 | The cholinergic system in Alzheimer's disease |
| Q52091302 | The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers. |
| Q45933581 | The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. |
| Q34092740 | Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases. |
| Q37217139 | [(123)I]-IBVM SPECT imaging of cholinergic systems in multiple system atrophy: A specific alteration of the ponto-thalamic cholinergic pathways (Ch5-Ch6). |
| Q35264378 | α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease |
Search more.